GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nanjing Leads Biolabs Co 9887.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

37.68

+3.06%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Nanjing Leads Biolabs Co

Its shares trade on HKEX under the ticker 9887.HK. It has been listed since 25 July 2025. In the fiscal year to 31 December 2025, it reported revenue of CN¥230.2m and a net loss of CN¥274.6m. At that date it held total assets of CN¥2.08bn and shareholders' equity of CN¥1.48bn.

Nanjing Leads Biolabs Co., Ltd. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2025-07-25. The Company’s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The firm's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The firm has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The firm mainly conducts its business in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Jul 2025
Employees
195

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Nanjing, Jiangsu with 195 employees
  • Main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007
  • Proprietary technology platforms include LeadsBod and X-body

Weaknesses

  • IPO scheduled for 2025-07-25
  • Primarily operates in the domestic market
  • No mention of international presence or global market reach

Opportunities

  • LBL-024 targets multiple cancer types including SCLC and NSCLC
  • Proprietary platforms may support future drug development
  • Domestic market focus could benefit from local healthcare growth

Threats

  • IPO date is in the future (2025-07-25)
  • Limited market presence outside domestic market
  • No information on competitive landscape or market saturation

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.